InforSense KDE, will provide Bayer with a highly flexible rapid application development platform to optimise its drug discovery decision-making
Bayer Healthcare has selected InforSense technology to enhance its drug discovery informatics infrastructure.
InforSense's workflow-based integrative analytics environment, InforSense KDE, will provide Bayer with a highly flexible rapid application development platform to optimise its drug discovery decision-making.
"To identify and optimise potential drug leads, Bayer's chemists need both rapid processing of large compound libraries via chemical cartridge technology coupled with easy access to best of breed proprietary and third party analytic tools and visualisations," said Alexander Hillisch, head of computational chemistry at Bayer Healthcare.
"InforSense Open Discovery Workflow technology offers the appropriate environment for rapidly composing data and applications, including our in-house in silico Admet tools, to optimise our high-throughput cheminformatics analysis".
"We are delighted that Bayer has chosen InforSense," commented Joseph Donahue, chief business officer, InforSense.
"InforSense KDE will facilitate the composition, integration and deployment of a wide range of cheminformatics applications by giving Bayer's computational chemists access to their chosen set of tools via cutting-edge workflow technology".
Bayer HealthCare, a subsidiary of Bayer, is one of the world's leading innovative companies in the health care and medical products industry.
In 2004, the Bayer HealthCare subgroup generated sales amounting to some euro8.5billion.
The company combines the global activities of the divisions animal health, biological products, consumer care, diabetes care, diagnostics and pharmaceuticals.
Bayer HealthCare employed 35,300 people worldwide in 2004.
Bayer HealthCare says its aim is to discover and manufacture innovative products that will improve human and animal health worldwide.
The products enhance well-being and quality of life by diagnosing, preventing and treating disease.
InforSense says it enables organisations to orchestrate and optimise their business-critical decision-making processes.
Leading pharmaceutical and biotechnology companies, financial services companies, and research institutes are using the company's flagship product, InforSense KDE, to enhance productivity across life science R and D, healthcare and business analytics.
The company is privately held, with European headquarters in London, UK and North American headquarters in Cambridge, Massachusetts.
Using InforSense KDE, enterprises rapidly integrate and deliver virtually any data source, analytic software tool, service or application within a single informatics framework.
Users link these components via visual workflows to dynamically answer any question using their data, however complex or transient.
Organisations can also mine their analytical processes to discover and deploy expertise and best practices.
InforSense KDE provides an open, extensible service-oriented architecture, built using industry standards including J2EE, XML, and WSDL.
The InforSense Oracle Edition is a state-of-the-art solution for enterprise-wide integrative analytics using Oracle's advanced information management and processing capabilities.
